Special Issue

Human Stem Cells in Disease Modelling and Treatment

Message from the Guest Editors

Over the last few decades, human stem cells have gained significant attention in biomedical research due to their unprecedented applications, both in terms of disease modelling and therapy. In addition, although rodents have been widely used as a model, they often fail to mirror the pathophysiology of human diseases due to species-specific differences. This Special Issue of *Biomedicines* aims to highlight the most recent advances in the field of human stem cell modelling, translation, and clinical application. Topics of interest include, but are not limited to, the following:

- Novel applications of human stem cells to study disease mechanisms;
- The use of human stem cells in regenerative medicine;
- Obstacles related to the cGMP compliance of human stem cells in regenerative medicine applications;
- Other limitations in the clinical translation of human stem cells for regenerative medicine.

Guest Editors

Dr. Sofia M. Calado

Faculty of Sciences and Technology, University of Azores-Polo de Ponta Delgada, Rua da Mãe de Deus, 9500-321 São Miguel, Azores, Portugal

Dr. Álvaro Plaza Reyes

Department of Regeneration and Cell Therapy, Andalusian Molecular Biology and Regenerative Medicine Centre (CABIMER), Avda. Américo Vespucio 24, 41092 Seville, Spain

Deadline for manuscript submissions

closed (31 May 2025)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).